UNICREDIT BANK/PUT/ELI LILLY & CO/800/0.1/19.03.25 | Market Closed - BOERSE MUENCHEN 03:41:19 2024-07-12 pm EDT | ||
| 3.3 EUR | -6.25% |
|
| Current month | -16.46% | ||
| 1 month | -34.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 3.3 | -6.25% |
| 24-07-11 | 3.52 | +1.44% |
| 24-07-10 | 3.47 | -10.10% |
| 24-07-09 | 3.86 | -0.52% |
| 24-07-08 | 3.88 | -4.90% |
Real-time BOERSE MUENCHEN
Last update July 12, 2024 at 03:41 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD4NBD |
| ISIN | DE000HD4NBD4 |
| Date issued | 2024-04-15 |
| Strike | 800 $ |
| Maturity | 2025-03-19 (249 Days) |
| Parity | 10 : 1 |
| Emission price | 10.24 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.53 € |
|---|---|
| Lowest since issue | 3.3 € |
| Spread | 0.21 € |
| Spread % | 6.33% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
948.4
USD
Average target price
894.8
USD
Spread / Average Target
-5.65%
- Stock Market
- Warrants
- Warrant
